The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries

INTRODUCTION: New biosimilars of monoclonal antibodies are anticipated to bring significant cost savings and increase access to treatment. The rituximab biosimilar CT-P10 has recently been approved in Europe in all indications held by reference rituximab (RTX), including rheumatoid arthritis, non-Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Gulácsi, László, Brodszky, Valentin, Baji, Petra, Rencz, Fanni, Péntek, Márta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427122/
https://www.ncbi.nlm.nih.gov/pubmed/28397080
http://dx.doi.org/10.1007/s12325-017-0522-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427122/
https://www.ncbi.nlm.nih.gov/pubmed/28397080
http://dx.doi.org/10.1007/s12325-017-0522-y

Ejemplares similares